Methods for assessment and treatment of mood disorders via single nucleotide polymorphisms analysis

A mood disorder panel assay to guide therapeutic treatment by determining the presence of SNPs that alter the function or expression of:

• the SERT gene;
• one or more of:
• DRD2, MTHF, COMT genes;
• one or more of:
• CACNA1C;
• and one or more of MTHFR, COMT and/or CYP2D6.

A method of treating a patient for a mood disorder comprising:

• determining the genotype of a polymorphism in each of the SERT, BDNF, CACNA1C, MTHFR/COMT and DRD2 genes;
• advising a treatment based upon the results of said testing wherein the treatment comprises:
• prescribing at least one of tianeptine and other SSRE for patients having a SERT short allele;
• prescribing at least one of Aniracetam and Nefiracetam for patients having the Val66Met form of BDNF;
• prescribing at least one of a calcium channel antagonists, an L-type voltage gated calcium channel agonist, and a member of the ARB class of drugs, and Candesartan for patients having either the rs1006737 or the rs1006737 variant of CACNA1C;
• prescribing at least one of a methylating agent, MTHF, S adenosylmethionine, a dopamine agonists, a MAO inhibitor, and a stimulant, for patients having either the C677T MTHFR variant or the 158val/val allele of the COMT gene;
• and
• prescribing at least one of an atypical neuroleptics which preferentially inhibits 5HT2A over DRD2 and Clozaril for patients having the −141C Ins/Del.

A method of treating a patient for a mood disorder comprising:

• determining the genotype of a polymorphism in each of the SERT, BDNF, CACNA1C, MTHFR/COMT and DRD2 genes;
• providing a treatment based upon the results of said testing, wherein the treatment comprises:
• prescribing at least one of tianeptine and other SSRE for patients having a SERT short allele;
• prescribing at least one of Aniracetam and Nefiracetam for patients having the Val66Met form of BDNF;
• prescribing at least one of a calcium channel antagonists, an L-type voltage gated calcium channel agonist, and a member of the ARB class of drugs, and Candesartan for patients having either the rs1006737 or the rs1006737 variant of CACNA1C;
• prescribing at least one of a methylating agent, MTHF, S adenosylmethionine, a dopamine agonists, a MAO inhibitor, and a stimulant, for patients having either the C677T MTHFR variant or the 158val/val allele of the COMT gene;
• and
• prescribing at least one of an atypical neuroleptics which preferentially inhibits 5HT2A over DRD2 and Clozaril for patients having the −141C Ins/Del.